Menow Sunscreen Pressed Powder Recalled Due to CGMP Deviations

Key Takeaways:

• The US Food and Drug Administration (FDA) has issued a voluntary Class II recall for Menow sunscreen pressed powder, SPF35, PA+++, 9 g/0.32 oz. The affected batch has been identified as Lot 2024/10/11 (expires October 2027), containing 2970 units.
• The recall was initiated by Shantou Qiwei Industrial Co, Ltd due to Current Good Manufacturing Practice (CGMP) deviations, a quality issue that is likely to cause temporary or medically reversible adverse health consequences or has a low probability of serious adverse health consequences.
• Menow sunscreen pressed powder is used to prevent sunburn.

The FDA has issued a Class II recall for Menow sunscreen pressed powder, SPF35, PA+++, 9 g/0.32 oz, affecting 2970 units. This product is manufactured and being recalled by Shantou Qiwei Industrial Co, Ltd based in Shantou, China. The recall was initiated on August 8, 2026, and received a Class II classification on September 18, 2026. A Class II classification means the use of this product is likely to cause temporary or medically reversible adverse health consequences or has a low probability of serious adverse health consequences.

The recall was initiated due to CGMP deviations. This deficiency affects Lot 2024/10/11, which will expire in October 2027. Shantou Qiwei Industrial Co sent out a public notice via letter; no press release has been issued for this recall.

Menow sunscreen pressed powder is used to protect the skin from UV rays and prevent sunburn. Pharmacists should identify and quarantine Lot 2024/10/11, remove it from inventory, and coordinate with prescribers to provide an alternative supply.

Reference

FDA. Enforcement Report. September 30, 2026. Accessed September 30, 2026. https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=222012